Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

Heise T, Zijlstra E, Mari A, Roell WC, Mather KJ, Haupt A, Flevaris P, Liao R, Chua L, Harris C, Pratt EJ

Diabetes, obesity & metabolism2 Jun 2026

PMID42229460PMCIDPMC13341334DOI10.1111/dom.70863PepBankPUB-42229460

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study16

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In T2D on metformin, dulaglutide increased cDI by 0.5 from baseline.
In plain wordsIn people with diabetes on metformin, dulaglutide increased the clamp disposition index from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseClamp disposition index
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
cDI increase
0.5
dulaglutide arm, 12-week increase from baseline
cDI change
181%
dulaglutide arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946001
02HumanRandomized controlled trialEfficacy outcome
In T2D on metformin, dulaglutide increased the M value by 0.2 from baseline.
In plain wordsIn people with diabetes on metformin, dulaglutide increased the insulin sensitivity measure from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseInsulin sensitivity M value
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
M value increase
0.2
dulaglutide arm, 12-week increase from baseline
M value change
10.4%
dulaglutide arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946002
03HumanRandomized controlled trialEfficacy outcome
In T2D on metformin, dulaglutide increased ISR by 191.1 from baseline.
In plain wordsIn people with diabetes on metformin, dulaglutide increased insulin secretion from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseInsulin secretion rate
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
ISR increase
191.1
dulaglutide arm, 12-week increase from baseline
ISR change
163.6%
dulaglutide arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946003
04HumanRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater cDI augmentation than macupatide alone.
In plain wordsIn people with diabetes, adding dulaglutide to macupatide produced a numerically greater clamp disposition index increase.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination cDI versus macupatide
Study
n: not reported in source
Comparator
macupatide alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
12-week increase in cDI
1 pmol*m-2*L*min-2*kg-1
combination arm
12-week percent change in cDI
321.5%
combination arm
12-week increase in cDI
0.2 pmol*m-2*L*min-2*kg-1
macupatide arm
12-week percent change in cDI
63.2%
macupatide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946007
05HumanRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater M value augmentation than macupatide alone.
In plain wordsIn people with diabetes, adding dulaglutide to macupatide produced a numerically greater insulin sensitivity increase.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination M value versus macupatide
Study
n: not reported in source
Comparator
macupatide alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
12-week increase in M value
2 mg*kg-1*min-1
combination arm
12-week percent change in M value
38.3%
combination arm
12-week increase in M value
1.3 mg*kg-1*min-1
macupatide arm
12-week percent change in M value
33.1%
macupatide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946008
06HumanRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater ISR augmentation than macupatide alone.
In plain wordsIn people with diabetes, adding dulaglutide to macupatide produced a numerically greater insulin secretion increase.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination ISR versus macupatide
Study
n: not reported in source
Comparator
macupatide alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 12 weeksAs given in this study (human).
Measurements
12-week increase in ISR
225.3 pmol*min-1*m-2
combination arm
12-week percent change in ISR
192.9%
combination arm
12-week increase in ISR
37.6 pmol*min-1*m-2
macupatide arm
12-week percent change in ISR
32.2%
macupatide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
Report a problemFND-4222946009

Studies that did not test the peptide alone10

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

07HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D on metformin, macupatide plus dulaglutide increased cDI by 1.0 from baseline.
In plain wordsIn people with diabetes on metformin, macupatide plus dulaglutide increased the clamp disposition index from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination clamp disposition index
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
cDI increase
1
combination arm, 12-week increase from baseline
cDI change
321.5%
combination arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946004
08HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D on metformin, macupatide plus dulaglutide increased the M value by 2.0 from baseline.
In plain wordsIn people with diabetes on metformin, macupatide plus dulaglutide increased the insulin sensitivity measure from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination insulin sensitivity
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
M value increase
2
combination arm, 12-week increase from baseline
M value change
38.3%
combination arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946005
09HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D on metformin, macupatide plus dulaglutide increased ISR by 225.3 from baseline.
In plain wordsIn people with diabetes on metformin, macupatide plus dulaglutide increased insulin secretion from baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination insulin secretion
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
ISR increase
225.3
combination arm, 12-week increase from baseline
ISR change
192.9%
combination arm
Source sentences
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946006
10HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater cDI augmentation than dulaglutide alone.
In plain wordsIn people with diabetes, the combination increased the clamp disposition index numerically more than dulaglutide alone.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination cDI versus dulaglutide
Study
n: not reported in source
Comparator
dulaglutide alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
12-week increase in cDI
1 pmol*m-2*L*min-2*kg-1
combination arm
12-week percent change in cDI
321.5%
combination arm
12-week increase in cDI
0.5 pmol*m-2*L*min-2*kg-1
dulaglutide arm
12-week percent change in cDI
181%
dulaglutide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946010
11HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater M value augmentation than dulaglutide alone.
In plain wordsIn people with diabetes, the combination increased insulin sensitivity numerically more than dulaglutide alone.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination M value versus dulaglutide
Study
n: not reported in source
Comparator
dulaglutide alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
12-week increase in M value
2 mg*kg-1*min-1
combination arm
12-week percent change in M value
38.3%
combination arm
12-week increase in M value
0.2 mg*kg-1*min-1
dulaglutide arm
12-week percent change in M value
10.4%
dulaglutide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946011
12HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In T2D, macupatide plus dulaglutide produced numerically greater ISR augmentation than dulaglutide alone.
In plain wordsIn people with diabetes, the combination increased insulin secretion numerically more than dulaglutide alone.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseCombination ISR versus dulaglutide
Study
n: not reported in source
Comparator
dulaglutide alone
Outcome group
Glycemic control · Metabolic and weight
Measurements
12-week increase in ISR
225.3 pmol*min-1*m-2
combination arm
12-week percent change in ISR
192.9%
combination arm
12-week increase in ISR
191.1 pmol*min-1*m-2
dulaglutide arm
12-week percent change in ISR
163.6%
dulaglutide arm
Source sentences
Summary
Combination therapy was numerically greater than both monotherapies in augmenting all indices.
Summary
The 12-week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%).
3 context sentences(design, population, supporting numbers)
Summary · context
Insulin sensitivity (M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12-week treatment.
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946012
13HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In the T2D trial including dulaglutide, injection site reactions were among the most frequent adverse events across treatments.
In plain wordsIn the diabetes trial, injection site reactions were common across treatments. The abstract did not separate dulaglutide results.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedInjection site reactions
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
The most frequent adverse events were injection site reactions and diarrhoea.
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946013
14HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In the T2D trial including dulaglutide, diarrhoea was among the most frequent adverse events across treatments.
In plain wordsIn the diabetes trial, diarrhoea was common across treatments. The abstract did not separate dulaglutide results.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedDiarrhoea
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
The most frequent adverse events were injection site reactions and diarrhoea.
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946014
15HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In the T2D trial including dulaglutide, treatment-emergent adverse event discontinuations were uncommon across treatments.
In plain wordsIn the diabetes trial, adverse event discontinuations were uncommon across treatments.
Peptide
Dulaglutide (Trulicity)
Outcome
Direction not reportedAdverse event discontinuations
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Source sentences
Summary
Study discontinuations due to treatment-emergent adverse events were uncommon.
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946015
16HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialSafety outcome
In the T2D trial including dulaglutide, no deaths occurred during the study across treatments.
In plain wordsNo deaths occurred in the diabetes trial across treatments. The abstract did not separate dulaglutide results.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDeaths
Study
n: not reported in source
Outcome group
Mortality · Whole body
Source sentences
Summary
There were no deaths during the study.
2 context sentences(design, population, supporting numbers)
Summary · context
This Phase 1b, randomised, double-blind clinical trial investigated the contribution of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin.
Summary · context
Participants were randomised to receive the long-acting GIP receptor agonist macupatide, dulaglutide or both combined.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-4222946016

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial.

Summary

Results from this study16

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords